Incyte and Eli Lilly’s Janus kinase (JAK) 1/2 inhibitors—Jakafi (ruxolitinib) and Olumiant (baricitinib), respectively—may have a mechanism edge over Pfizer’s JAK 1/3 inhibitor Xeljanz (tofacitinib) in Covid-19. However, Theravance Biopharma’s pan-JAK inhibitor TD-0903 stands out for its nebulised mode of administration but there is still uncertainty about its value.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045